Abrdn Life Sciences Investors (NYSE:HQL) Short Interest Update

Abrdn Life Sciences Investors (NYSE:HQL) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 77,800 shares, a growth of 212.4% from the December 31st total of 24,900 shares. Based on an average trading volume of 93,900 shares, the days-to-cover ratio is currently 0.8 days.

Insider Buying and Selling at Abrdn Life Sciences Investors

In related news, major shareholder Saba Capital Management, L.P. sold 11,674 shares of the stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $14.12, for a total value of $164,836.88. Following the transaction, the insider now owns 3,418,349 shares in the company, valued at approximately $48,267,087.88. This represents a 0.34 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 10.06% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Abrdn Life Sciences Investors

Several hedge funds have recently added to or reduced their stakes in the company. Future Financial Wealth Managment LLC bought a new position in shares of Abrdn Life Sciences Investors during the 3rd quarter valued at about $30,000. Ashton Thomas Securities LLC acquired a new stake in Abrdn Life Sciences Investors in the 3rd quarter valued at approximately $148,000. Sanctuary Advisors LLC acquired a new stake in Abrdn Life Sciences Investors in the 2nd quarter valued at approximately $154,000. Kingswood Wealth Advisors LLC acquired a new stake in Abrdn Life Sciences Investors in the 4th quarter valued at approximately $160,000. Finally, Kapstone Financial Advisors LLC acquired a new stake in Abrdn Life Sciences Investors in the 3rd quarter valued at approximately $177,000. Institutional investors own 32.21% of the company’s stock.

Abrdn Life Sciences Investors Stock Up 0.2 %

Shares of HQL traded up $0.03 during mid-day trading on Thursday, hitting $14.16. The company’s stock had a trading volume of 98,994 shares, compared to its average volume of 114,221. The stock’s 50-day moving average is $13.75 and its two-hundred day moving average is $14.62. Abrdn Life Sciences Investors has a one year low of $12.76 and a one year high of $15.90.

Abrdn Life Sciences Investors Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 10th. Stockholders of record on Thursday, November 21st were paid a $0.50 dividend. The ex-dividend date of this dividend was Thursday, November 21st. This is a positive change from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.49. This represents a $2.00 dividend on an annualized basis and a dividend yield of 14.12%.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.